Behavioural dysfunctions are common in patients with Alzheimer disease (AD). Up to 67% of AD patients (pts) present such disturbances, which appear to be associated with endogenous and exogenous factors such as disease stage, environmental factors, and AD genotype. Aim of this study is to assess the relationship between apolipoprotein E (APO E) status and behavioural symptoms in AD pts. Sixty probable AD pts (16 male and 44 female; mean age ± SD: 69 ± 8.1; mean age of onset ± SD: 64.2 ± 7.4; disease duration ± SD: 5 ± 2.5; mean Mini-Mental State Examination score ± SD: 16.6 ± 6.2), according to NINDCS-ADRDA criteria, were assessed with the Neuropsychiatric Inventory (NPI) prior to beginning any anti-dementia treatment and their APO E genotype was determined. Among the population studied 5.7% of pts were E2/E2, 57.1% were E3/E3 and 37.2% was with at least one APOE E4 allele. No correlation was found between APOE genotype and any of the 12 non-cognitive symptoms assessed with NPI, even after controlling for the effect of age onset, sex, duration of illness, and severity of dementia. These findings do not support the hypothesis that neuropsychiatric manifestations of AD are different in patients with the APOE E4 allele.
Apolipoprotein E genotype and behavioural change in AD
TOGNONI, GLORIA;SICILIANO, GABRIELE;MANCUSO, MICHELANGELO;ROCCHI, ANNA;MURRI, LUIGI
2000-01-01
Abstract
Behavioural dysfunctions are common in patients with Alzheimer disease (AD). Up to 67% of AD patients (pts) present such disturbances, which appear to be associated with endogenous and exogenous factors such as disease stage, environmental factors, and AD genotype. Aim of this study is to assess the relationship between apolipoprotein E (APO E) status and behavioural symptoms in AD pts. Sixty probable AD pts (16 male and 44 female; mean age ± SD: 69 ± 8.1; mean age of onset ± SD: 64.2 ± 7.4; disease duration ± SD: 5 ± 2.5; mean Mini-Mental State Examination score ± SD: 16.6 ± 6.2), according to NINDCS-ADRDA criteria, were assessed with the Neuropsychiatric Inventory (NPI) prior to beginning any anti-dementia treatment and their APO E genotype was determined. Among the population studied 5.7% of pts were E2/E2, 57.1% were E3/E3 and 37.2% was with at least one APOE E4 allele. No correlation was found between APOE genotype and any of the 12 non-cognitive symptoms assessed with NPI, even after controlling for the effect of age onset, sex, duration of illness, and severity of dementia. These findings do not support the hypothesis that neuropsychiatric manifestations of AD are different in patients with the APOE E4 allele.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
